Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD38 CAR-T Cells-Sorrento Therapeutics (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sorrento Therapeutics

    • Most Recent Events

    • 19 Jun 2019 According to an Sorrento Therapeutics media release, this trial is progressing and to be concluded in 2019. The company looks forward to publicly discussing the study data later in 2019.
    • 19 Jun 2019 According to an Sorrento Therapeutics media release, patient recruitment is currently ongoing at two clinical sites and additional sites will be opened in the second half of 2019.
    • 01 Nov 2018 According to the Sorrento Therapeutics media release, first patients were dosed at two clinical sites University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top